about
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancerChromatin immunoprecipitation from fixed clinical tissues reveals tumor-specific enhancer profiles.Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer.Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer: Long-term Outcomes From a Phase 1 Study.Comprehensive Molecular Characterization of Muscle-Invasive Bladder CancerEverolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinomaManagement of metastatic bladder cancerThe Cancer Genome Atlas Expression Subtypes Stratify Response to Checkpoint Inhibition in Advanced Urothelial Cancer and Identify a Subset of Patients with High Survival ProbabilityNovel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer ModelsTreatment of Metastatic Urothelial Cancer in 2018
P50
Q29617772-2ED6E6E9-E3D6-4D52-AF5A-4F4BA1B53E03Q38380810-0683DEA2-F5F5-4FB6-889C-98476BC62DC8Q47111129-292D68D3-9756-4C81-9F2B-B24CFEF19FCEQ50104337-5CBD5CB5-69DA-424C-864F-A16EA8F90F9EQ90872171-2DB786C5-3963-4438-910A-149C370802CFQ91472224-27B5E6DE-3582-47FC-83B7-C6C059373439Q91570402-4B1227BA-ED27-43BD-A061-568479F16B85Q92244263-147B1432-4092-4E44-A3CE-0D744BC3D2A5Q92500740-5BAEEF22-7779-4E31-9C74-ADFF8B27E3DDQ93023789-557E8202-53B5-4935-844E-E2F77F899B0B
P50
description
researcher
@en
wetenschapper
@nl
name
Joaquim Bellmunt
@en
Joaquim Bellmunt
@nl
type
label
Joaquim Bellmunt
@en
Joaquim Bellmunt
@nl
prefLabel
Joaquim Bellmunt
@en
Joaquim Bellmunt
@nl
P31
P496
0000-0003-2328-3421